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Epinephrine, norepinephrine and isoproterenol completely inhibited insulin-stimulated 2-deoxyglucose 
uptake by rat adipocytes, but only when adenosine was prevented from accumulating in the incubation 
medium by addition of adenosine deaminase. Basal uptake rates were not affected. The effects were not 
observed in the presence of adenosine deaminase plus ~-phenylisopropyl adenosine (a non-metabolizable 
adenosine analogue), suggesting that it is the lowered adenosine ievei rather than the presence of the 
enzyme itself which allows the catecholamines to inhibit insulin action. The inhibitory effects of the 
catecholamines were blocked by propranolol but not phentolamine, suggesting that they are mediated via 
,&adrenergic receptors. 
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1. INTRODUCTION 
One of the primary effects of insulin is to in- 
crease the rate of glucose transport and utilization 
in muscle and adipose tissue (for review see [I]). 
Recently it has been demonstrated that 
catecholamines can oppose this effect of insulin on 
muscle [2]. However, studies of effects of 
catecholamines on glucose utilization in adipose 
tissue have given conflicting results. Several 
authors have reported that catecholamines actually 
mimic the effect of insulin on glucose transport 
and utilization in isolated adipose tissue and 
adipocytes [3-51. 
Therefore it was of interest to investigate the ef- 
fects of catecholamines on glucose transport in 
adipocytes, in the presence and in the absence of 
adenosine deaminase. The results demonstrate that 
catecholamines can inhibit insulin-stimulated 
2-deoxyglucose uptake, but only in the presence of 
adenosine deaminase. This suggests that adenosine 
released from the cells attenuates the ability of 
catecholamines to inhibit insulin-stimulated 
glucose transport, and that adenosine and 
catecholamines are regulators of insulin action in 
adipose tissue. 
Recently it has been reported that glucagon can 
antagonize the effect of insulin on glucose 
transport in adipocytes [6]. However, the effect of 
glucagon was only observed if adenosine, which is 
produced spontaneously by isolated adipocytes [7], 
was prevented from accumulating in the incuba- 
tion medium by addition of adenosine deaminase. 
2. MATERIALS AND METHODS 
Present address: Division of Endocrinology, J-226, 
University of Florida, Gainesville, FL 32610, USA 
Porcine insulin was generously given by Dr 
Ronald Chance of Eli Lilly (Indianapolis, IN). 
Bovine serum albumin (BSA) (fraction V) was pur- 
chased from Armour Pharmaceuticals (Phoenix, 
AZ). Collagenase was from Worthington 
Biochemicals (Freehold, NJ). L-[ l-3H]glucose and 
2-deoxy-D-[ 1 -‘H]glucose were from New England 
Nuclear (Boston, MA). 2-Deoxy-D-glucose, 
~-2-hydroxyethylpiper~ine-~‘-2~thanesulphoni~ 
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acid (HEPES), N-tris[hydroxymethyl]methyl 
glycine (Tricine), epinephrine, norepinephrine, 
isoproterenol, propranolol and adenosine 
deaminase (EC 3.5.4.4) were from Sigma (St 
Louis, MO). Phentolamine was from CIBA (Sum- 
mit, NJ). Adenosine deaminase was supplied as a 
suspension in 3.2 M (NH&Sod. Before use the en- 
zyme was dialyzed against 2 x 500 vol. of 154 mM 
NaCl, 10 mM HEPES (pH 7.4) to remove 
(NH&S04. Male Sprague-Dawley rats weighing 
190-230 g were purchased from Charles River 
(Cambridge, MA). 
Adipocytes were isolated from epididymal fat 
pads as in [S]. Cells were filtered through 250pm 
nylon mesh, centrifuged at 25 x g for PO s and 
washed 3-times in the incubation buffer (see 
below). The cells (-2 x 105/ml) were then in- 
cubated with shaking for 1 h at 37°C in a buffer 
containing 137 mM NaCI, 5 mM KCI, 4.2 mM 
NaHC03, 1.3 mM CaC12, 0.5 mM MgClz, 
0.4 mM MgS04, 10 mM HEPES, 10 mM Tricine 
and BSA (10 mg/ml) (pH 7.4) and additions as 
described in the text and figure legends. 
At the end of the incubation period glucose 
transport was measured by the 2-deoxyglucose up- 
take method [9] as follows: 2-Deoxy-D- 
[ l-3H]glucose (spec. act. 1.6 mCi/mmol) was add- 
ed to a final concentration of 0.1 mM. The assays 
were terminated 3 min later by transferring 200-~1 
samples of the cell suspension to plastic microtubes 
containing silicone oil (100 ~1). The tubes were cen- 
trifuged for 30 s in a Beckman ‘Microfuge’, and 
the assay was considered terminated when cen- 
trifugation began. The tubes were cut through the 
oiI layer with a razor blade, and the radioactivity 
in the ceil pellet was measured in a liquid scintilla- 
tion counter. In each experiment, similar incuba- 
tions were performed using L-[l-3H]glucose in 
place of 2-deoxyglucose to determine the amount 
of sugar trapped in the extracellular water space of 
the cell layer. All data have been corrected for this 
factor. 
Adipocytes were counted by a modification of 
Method III in [lo]. The cells were fixed in 2% 
osmium tetroxide in 50 mM collidine buffer (made 
isotonic with NaCI) for 24 h at 37”C, and then 
counted in a Coulter counter, model ZB. All 
results have been normalized to a cell concentra- 
tion of 2.5 x 10’ cells/ml. 
3. RESULTS 
3.1. Effects of cutecholamines on glucose 
transport 
In the absence of adenosine deaminase, 
epinephrine, norepinephrine and isoproterenol had 
no effect on either basal or insulin-stimulated 
2-deoxyglucose uptake (fig.lA). In the presence of 
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Fig. 1. Effects of catecholamines on basal and insulin-stimulated glucose transport in the absence (A) or in the presence 
(B) of adenosine deaminase. Adipocytes were incubated at 37°C without (open symbols) or with (closed symbols) insulin 
(25 nglml) plus the indicated concentrations of epinephrine (o,e), norepinephrine (A, A) or isoproterenol (TV ,8). 
After 1 h, 2-deoxyglucose uptake was measured as described in section 2. 
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adenosine deaminase however, all 3 
~atecholam~nes completefy inhibited the effect of 
insulin on 2-deoxygtucose uptake (fig.lB). There 
was no effect of cateeholamines on basal uptake 
rates in the presence of the enzyme. Half- 
maximally effective concentrations of the 
catecholamines in the presence of the enzyme were 
about 0.3 PM, 0.1 PM and 0.02pM for 
epinephrine, norepinephrine and isoproterenol, 
respectively. Thus catecholamines inhibit the effect 
of insulin on glucose transport, but only in the 
presence of adenosine deaminase. 
The effect of isoproterenol on insulin-stimulated 
2-deoxyglucose uptake was not observed when 
~-phe~yliso~ropyl adenosine (an adenosine 
analogue which is not deaminated by adenosine 
deaminase) was included together with the enzyme 
(fig.2). Similarly, epinephrine and norepinephrine 
did not inhibit the insulin-stimulated uptake rates 
when the analogue was included together with the 
enzyme (not shown). This suggests that in the 
presence of adenosine deaminase it is the lowered 
adenosine level, rather than the presence of the en- 
zyme itself, which allows the catecholamines to in- 
hibit the insulin effect. 
3.2. Effects of CT- ami ~-~~~~k~~~ 
In order to investigate which class of adrenergic 
1.6 
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Fig.2. Effect of isoproterenol on insulin-stimulated 
glucose transport in the presence or absence of 
adenosine deaminase and N6-phenylisopropyl 
adenosine. Adipocytes were incubated at 37°C with 
insulin (25 ng/ml) plus: (e) no further additions; (A) 
adenosine deaminase {lo pg/ml); (0) adenosine 
deaminase (10 pg/mQ and ~-~heny~iso~ropyl 
adenosine (0.1 pM]. After I h, 2-deoxyglucose uptake 
was measured as described in section 2. 
crbiocker P-blocker 
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Fig.3. Effects of adrenergic blocking agents on the 
ability of epinephrine to inhibit jnsulin-stimulated 
glucose transport in the presence of adenosine 
deaminase, Adipocytes were incubated at 37°C with 
adenosine deaminase (10 pg/ml) plus phentolamine or 
propranolol as indicated. After IO min insulin 
(25 &ml) and epinephrine (10pM) were added as 
indicated. After a further 1 h, 2-deoxyglucose uptake 
was measured as described in section 2. 
receptors mediates the effect of catecholamines on 
2-deoxyglucose uptake, the adrenergic blocking 
agents phentolamine (a-blocker) and propranolol 
@-blocker) were utilized. Cells were incubated 
with propranoiol or ~hen~olamine for 10 min prior 
to addition of hormones. ~hentoIamine did not af- 
fect the ability of epinephrine (10&M) to inhibit 
insulin-stimulated glucose transport in the 
presence of adenosine deaminase (fig.3). However, 
propranolol(l0 ,QM) completely blocked the effect 
of the catecholamine. Similarly, the effects of 
1 PM norepinephrine or 0.5 pM isoproterenol were 
prevented by the P-blocker but not the a-blocker 
(not shown). Therefore this effect of 
catecholamines seems to be mediated via @- 
adrenergic receptors. 
4. DISCUSSION 
2-Deoxyglucose is taken up by adipocytes by the 
D-glucose transport system and provides a good 
index of the rate of glucose transport [9]_ The 
results presented in this report demonstrate that 
catecholamines inhibit insulin-stimulated 
2-deoxyglucose uptake by adipocytes in the 
presence (but not absence) of adenosine 
deaminase, This catecholamine effect is not 
observed in the presence of the enzyme plus 
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~-phenyl~sopropyl adenosine (an adenosine 
analogue which is not deaminated by adenosine 
deaminase). Furthermore, adipocytes are known 
to release small amounts of adenosine into the in- 
cubation medium [7]. Taken together these obser- 
vations strongly suggest that catecholamines can 
antagonize the effect of insulin on glucose 
transport and that adenosine, released from the 
cells, can block this effect of catecholamines. 
It has previously been demonstrated that 
adenosine deaminase can decrease the insulin sen- 
sitivity of glucose utilization [l l] and glucose ox- 
idation (121 in adipocytes. This has recently been 
shown to result, at least partly, from a decrease in 
the insulin sensitivity of the glucose transport 
system [6]. Adenosine deaminase does not, by 
itself, alter the response of glucose transport to a 
maximally effective concentration of insulin, 
25 ng/ml [6]. Insulin has been used at a maximal 
concentration (25 ng/ml) throughout the current 
studies, which explains why adenosine deaminase 
by itself did not significantly alter the rate of 
glucose transport {see fig-l). However, in the 
presence of adenosine deaminase, catecholamines 
inhibit the effect of this maximally effective con- 
centration of insulin. Thus it appears that 
catecholamines and adenosine can interact to 
regulate the maximum response of glucose 
transport to insulin. 
The concentration of adenosine in adipose tissue 
in vivo is unknown. Similarly, the change in 
adenosine concentration produced by adenosine 
deaminase in the current studies is not known. 
Therefore it is difficult to assess the possible 
physiological significance of these findings. 
However, the current findings result from removal 
of adenosine produced spontaneously by isolated 
adipocytes. Therefore the cells are capable of pro- 
ducing sufficient adenosine to modify their 
response to insulin and catecholamines. This sug- 
gests that adenosine and catecholamines are 
regulators of insulin action in adipose tissue in 
vivo. 
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